Analyst questions the bigger picture for GILD, including risks and visibility challenges wavering in 2018.
Ahead of a conference call this afternoon with HIV doctors, RBC Capital analyst Michael Yee offers insight on Gilead Sciences, Inc. (NASDAQ:GILD) and …
